- Home
- LGO vs FLNA Comparison
LGO vs FLNA Comparison
Compare LGO & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGO | FLNA |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.8M | 61.8M |
| IPO Year | 2007 | 2000 |
Fundamental Metrics
Financial Performance| Metric | LGO | FLNA |
|---|---|---|
| Price | $0.68 | $0.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 534.7K | 233.6K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,119,000.00 |
| Revenue This Year | $50.56 | N/A |
| Revenue Next Year | $59.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.75 |
| 52 Week High | $2.70 | $2.03 |
Technical Indicators
Market Signals| Indicator | LGO | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 22.83 |
| Support Level | $0.61 | N/A |
| Resistance Level | $0.83 | $0.99 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 13.12 | 0.00 |
Price Performance
Historical ComparisonAbout LGO Largo Inc.
Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.